

within the comment period, the regulation would become effective on October 8, 1998. No adverse comments were received, and thus this notice confirms that this direct final rule will become effective on that date.

Issued in Burlington, MA, on September 3, 1998.

Bill Peacock,

Manager, Air Traffic Division, New England Region.

[FR Doc. 98-24420 Filed 9-10-98; 8:45 am]

BILLING CODE 4910-13-M

authority delegated to the Commissioner of Food and Drugs, notice is given that no objections or requests for a hearing were filed in response to the May 13, 1998, final rule. Accordingly, the amendments issued thereby are effective September 25, 1998.

Dated: September 1, 1998.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 98-24411 Filed 9-10-98; 8:45 am]

BILLING CODE 4160-01-F

the Commissioner of Food and Drugs, notice is given that no objections or requests for a hearing were filed in response to the May 12, 1998, final rule. Accordingly, the amendments issued thereby are effective September 24, 1998.

Dated: September 1, 1998.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 98-24413 Filed 9-10-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 3, 5, 10, 16, 25, 50, 56, 58, 71, 200, 201, 207, 210, 211, 310, 312, 314, 369, 429, 800, and 812

[Docket No. 98N-0210]

Removal of Regulations Regarding Certification of Drugs Composed Wholly or Partly of Insulin; Confirmation of Effective Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Direct final rule; confirmation of effective date.

SUMMARY: The Food and Drug Administration (FDA) published in the **Federal Register** of May 13, 1998, a direct final rule (63 FR 26694). The direct final rule amends the regulations regarding certification of drugs composed wholly or partly of insulin, and conforming and related amendments. This document confirms the effective date of the direct final rule.

EFFECTIVE DATE: The effective date of the direct final rule published at 63 FR 26694 is confirmed as September 25, 1998.

FOR FURTHER INFORMATION CONTACT: Wayne H. Mitchell, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

SUPPLEMENTARY INFORMATION: FDA solicited comments concerning the direct final rule for a 75-day period ending July 27, 1998. FDA stated that the effective date of the direct final rule would be on September 25, 1998, 60 days after the end of the comment period, unless any significant adverse comment was submitted to FDA during the comment period. FDA did not receive any significant adverse comments.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 430, 431, 432, 433, 436, 440, 441, 442, 443, 444, 446, 448, 449, 450, 452, 453, 455, and 460

[Docket No. 98N-0211]

Removal of Regulations Regarding Certification of Antibiotic Drugs; Confirmation of Effective Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Direct final rule; confirmation of effective date.

SUMMARY: The Food and Drug Administration (FDA) published in the **Federal Register** of May 12, 1998, a direct final rule (63 FR 26066). The direct final rule repealed FDA's regulations governing certification of antibiotic drugs. This document confirms the effective date of the direct final rule.

EFFECTIVE DATE: The effective date of the direct final rule published at 63 FR 26066 is confirmed as September 24, 1998.

FOR FURTHER INFORMATION CONTACT: Wayne H. Mitchell, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

SUPPLEMENTARY INFORMATION: FDA solicited comments concerning the direct final rule for a 75-day period ending July 27, 1998. FDA stated that the effective date of the direct final rule would be on September 24, 1998, 60 days after the end of the comment period, unless any significant adverse comment was submitted to FDA during the comment period. FDA did not receive any significant adverse comments.

Therefore, under the Federal Food, Drug, and Cosmetic Act, the Food and Drug Administration Modernization Act, and under authority delegated to

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs For Use In Animal Feeds; Bacitracin Methylene Disalicylate, Decoquinat, and Roxarsone; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a final rule that appeared in the **Federal Register** of July 17, 1998 (63 FR 38474). The document amended the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Alpharma Inc. The NADA provides for using approved bacitracin methylene disalicylate, decoquinat, and roxarsone Type A medicated articles to make combination drug Type C medicated broiler chicken feeds. The document was published with two typographical errors. This document corrects those errors.

EFFECTIVE DATE: July 17, 1998.

FOR FURTHER INFORMATION CONTACT: Carolyn C. Harris, Office of Policy (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-2994.

In FR Doc. 98-19025, appearing on page 38474 in the **Federal Register** of Friday, July 17, 1998, the following corrections are made:

1. On page 38475, in the third column, in amendatory instruction "2." the citation "(d)(3)(xv)" is corrected to read "(d)(3)(xvii)".

§ 558.76 [Corrected]

2. On page 38475, in the third column, in § 558.76 *Bacitracin methylene disalicylate*, paragraph "(d)(3)(xv)" is corrected to read "(d)(3)(xvii)".